Get started
Author

Ling‐Yuh Huw

Observed names: Ling-Y Huw, Ling-Yuh Huw
OpenAlex ID: A5114045957
Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer
2015 · Lisa Ryner, Yinghui Guan, et al. · Clinical Cancer Research · 107
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
2023 · Lihua E. Budde, Adam J. Olszewski, et al. · Nature Medicine · 101
PDF
A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
2016 · Vicky Makker, Fernando O. Recio, et al. · Cancer · 92
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort
2019 · Xiaoji Chen, Ching-Wei Chang, et al. · Clinical Cancer Research · 88
Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
2009 · Jiping Zha, Carol O'Brien, et al. · Molecular Cancer Therapeutics · 86
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
2023 · Stephen J. Schuster, Ling-Yuh Huw, et al. · Blood · 81
Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E
2002 · Yi-Xin (Jim) Wang, Baby Martin-McNulty, et al. · Atherosclerosis · 79
Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL
2023 · Monica E. Susilo, Chi‐Chung Li, et al. · Clinical and Translational Science · 78
Tctex2: A Sperm Tail Surface Protein Mapping to the t-Complex
1995 · Ling-Yuh Huw, Andrew S. Goldsborough, et al. · Developmental Biology · 52
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study
2021 · Maria Lia Palomba, Guillaume Cartron, et al. · Clinical Lymphoma Myeloma & Leukemia · 44
PDF
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
2022 · Radia M. Johnson, Xueping Qu, et al. · Nature Communications · 41
PDF
Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study
2023 · Michael L. Wang, Sarit Assouline, et al. · Blood · 36
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
2016 · Timothy R Wilson, Jianjun Yu, et al. · npj Breast Cancer · 29
PDF
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
2021 · John Mascarenhas, Francesco Passamonti, et al. · Blood Advances · 26
PDF
Age-Dependent Acceleration of Ischemic Injury in Endothelial Nitric Oxide Synthase-Deficient Mice: Potential Role of Impaired VEGF Receptor 2 Expression
2006 · Hu Sheng Qian, Micheline Monterio de Resende, et al. · Journal of Cardiovascular Pharmacology · 24
Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.
2022 · Stephen J. Schuster, Ling-Yuh Huw, et al. · Journal of Clinical Oncology · 23
Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
2019 · Genevive Hernandez, Ling-Yuh Huw, et al. · Blood · 18
Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL).
2021 · L Elizabeth Budde, Nilanjan Ghosh, et al. · Journal of Clinical Oncology · 17
Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
2022 · Adam J. Olszewski, L. Elizabeth Budde, et al. · Blood · 15
Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study
2023 · L. Elizabeth Budde, Adam J Olszewski, et al. · Blood · 9
A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
2024 · Chi‐Chung Li, Chi‐Chung Li, et al. · Clinical Pharmacology & Therapeutics · 8
PDF
Promising Clinical Data From Dose Escalation in a Phase Ib/ii Ongoing Study of Mosunetuzumab With Polatuzumab Vedotin for Relapsed/refractory B‐cell Non‐hodgkin’s Lymphoma
2021 · C Diefenbach, E Budde, et al. · Hematological Oncology · 4
PDF
Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study
2020 · Francesco Passamonti, Kate Burbury, et al. · Blood · 3
Baseline CD4 T Cells Are Associated with Improved Response to CD20-CD3 Bispecifics in Lymphoma
2023 · Christopher R. Bolen, Sumedha Roy, et al. · Blood · 2
Abstract LB-063: ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC
2020 · Radia Marie Johnson, Xueping Qu, et al. · Cancer Research · 2
Works count: 68
Citation count: 1,071
H-index: 17
I10-index: 19
Year
Topic
Type